A major, new study in The New England Journal of Medicine considers psilocybin and its potential for refractory depression. It’s received enthusiastic media coverage. Breakthrough drug? Overhyped headlines? Today, on Quick Takes, Dr. David Gratzer is joined by one of the study co-authors, Dr. Ishrat Husain Tier 2 Canada Research Chair and lead of the Mood Disorder Service at CAMH, to delve deeper into this headline-grabbing research.

During their discussion we learn:

• how to talk to your patients asking about using psilocybin therapeutically
• the encouraging results of the study – and the adverse effects as well
• how practical it would be to scale up the study into current treatment algorithms
• and if microdosing is really all its hyped-up to be.

Follow us on Twitter

THANKS FOR LISTENING!

Quick Takes is a production of the Center for Addiction and Mental Health. You can find links to the relevant content mentioned in the show and accessible transcripts of all the episodes we produce online at CAMH.ca and on the CAMH Global Learning Academy.

Follow CAMH Education on X (formerly known as Twitter) @camhEdu

Follow and subscribe to Reading of the Week where, every week, Dr. David Gratzer reviews research papers from the world of psychiatry.